Linked Life Data

9776115

Source:http://linkedlifedata.com/resource/pubmed/id/9776115

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9776115rdf:typepubmed:Citationlld:pubmed
pubmed-article:9776115lifeskim:mentionsumls-concept:C0003873lld:lifeskim
pubmed-article:9776115lifeskim:mentionsumls-concept:C0229671lld:lifeskim
pubmed-article:9776115lifeskim:mentionsumls-concept:C0034819lld:lifeskim
pubmed-article:9776115lifeskim:mentionsumls-concept:C0596473lld:lifeskim
pubmed-article:9776115pubmed:issue4lld:pubmed
pubmed-article:9776115pubmed:dateCreated1998-12-15lld:pubmed
pubmed-article:9776115pubmed:abstractTextThe value of measuring soluble interleukin-2 receptor (sIL-2R) in the sera of patients with joint pain as a predicting parameter for the future development of rheumatoid arthritis (RA) was examined. sIL-2R was measured by the ELISA method. Sixty-four patients with joint pain (suspected RA: sus-RA) but no bone or joint destruction were enrolled over 2 years and 47 were selected for the study. Eleven patients whose diagnosis was sus-RA after a year of observation were successively followed-up for 5 years. Two-thirds of the patients whose sIL-2R levels were higher than those of normal healthy adults (< 82 pmol/l; mean +2SD) developed RA within a year. On the other hand, one-quarter of the patients with normal levels of sIL-2R also developed RA within a year. The presence of two or three of the following three items in patients with joint pain without any bone and joint destruction was thus indicated to be useful for the early diagnosis of RA: elevated CRP level (> or = 1.0 mg/dl), positive rheumatoid factor (RF) (> or = 30 IU/ml) and an elevated sIL-2R level (> or = 100 pmol/l). Sensitivity and specificity were 72.7% and 96.0%, respectively. The probability of development of RA is expressed as P = 1/[1 + exp(2.673 - 0.01784 x sIL-2R - 0.4398 x CRP - 0.004835 x RF)], with R2 = 0.3083 and p<0.0005. On the other hand, the sIL-2R levels did not correlate with any future bone or joint changes within a year of observation. The above criteria may therefore hopefully justify the early treatment of patients with joint pain using drugs that can modify the patients' immune function. However, the validity of these criteria still need to be examined more thoroughly in the future.lld:pubmed
pubmed-article:9776115pubmed:languageenglld:pubmed
pubmed-article:9776115pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9776115pubmed:citationSubsetIMlld:pubmed
pubmed-article:9776115pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9776115pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9776115pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9776115pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9776115pubmed:statusMEDLINElld:pubmed
pubmed-article:9776115pubmed:issn0770-3198lld:pubmed
pubmed-article:9776115pubmed:authorpubmed-author:WadaTTlld:pubmed
pubmed-article:9776115pubmed:authorpubmed-author:YamamotoMMlld:pubmed
pubmed-article:9776115pubmed:authorpubmed-author:YasudaMMlld:pubmed
pubmed-article:9776115pubmed:authorpubmed-author:NonakaSSlld:pubmed
pubmed-article:9776115pubmed:authorpubmed-author:SuenagaYYlld:pubmed
pubmed-article:9776115pubmed:authorpubmed-author:NobunagaMMlld:pubmed
pubmed-article:9776115pubmed:authorpubmed-author:ShiokawaSSlld:pubmed
pubmed-article:9776115pubmed:issnTypePrintlld:pubmed
pubmed-article:9776115pubmed:volume17lld:pubmed
pubmed-article:9776115pubmed:ownerNLMlld:pubmed
pubmed-article:9776115pubmed:authorsCompleteYlld:pubmed
pubmed-article:9776115pubmed:pagination311-7lld:pubmed
pubmed-article:9776115pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:9776115pubmed:meshHeadingpubmed-meshheading:9776115-...lld:pubmed
pubmed-article:9776115pubmed:meshHeadingpubmed-meshheading:9776115-...lld:pubmed
pubmed-article:9776115pubmed:meshHeadingpubmed-meshheading:9776115-...lld:pubmed
pubmed-article:9776115pubmed:meshHeadingpubmed-meshheading:9776115-...lld:pubmed
pubmed-article:9776115pubmed:meshHeadingpubmed-meshheading:9776115-...lld:pubmed
pubmed-article:9776115pubmed:meshHeadingpubmed-meshheading:9776115-...lld:pubmed
pubmed-article:9776115pubmed:meshHeadingpubmed-meshheading:9776115-...lld:pubmed
pubmed-article:9776115pubmed:meshHeadingpubmed-meshheading:9776115-...lld:pubmed
pubmed-article:9776115pubmed:meshHeadingpubmed-meshheading:9776115-...lld:pubmed
pubmed-article:9776115pubmed:meshHeadingpubmed-meshheading:9776115-...lld:pubmed
pubmed-article:9776115pubmed:meshHeadingpubmed-meshheading:9776115-...lld:pubmed
pubmed-article:9776115pubmed:meshHeadingpubmed-meshheading:9776115-...lld:pubmed
pubmed-article:9776115pubmed:meshHeadingpubmed-meshheading:9776115-...lld:pubmed
pubmed-article:9776115pubmed:meshHeadingpubmed-meshheading:9776115-...lld:pubmed
pubmed-article:9776115pubmed:meshHeadingpubmed-meshheading:9776115-...lld:pubmed
pubmed-article:9776115pubmed:year1998lld:pubmed
pubmed-article:9776115pubmed:articleTitleSerum interleukin-2 receptor for the early diagnosis of rheumatoid arthritis.lld:pubmed
pubmed-article:9776115pubmed:affiliationDepartment of Clinical Immunology, Medical Institute of Bioregulation, Kyushu University, Oita, Japan.lld:pubmed
pubmed-article:9776115pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9776115pubmed:publicationTypeComparative Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9776115lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9776115lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9776115lld:pubmed